Clinical Trial Update: Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating molecular imaging of gastrin-releasing peptide receptors using Technetium-99m-labeled DB8 in prostate cancer and breast cancer; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Prostate Cancer

Drugs mentioned

• Technetium-99m DB8 (DB8)

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Prostate Cancer, Breast Cancer | Phase 1 | Status: COMPLETED